Walgreens Beats on Q2 Earnings, Withdraws Fiscal 2025 View, Stock Down

Core Insights - Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of 63 cents for Q2 fiscal 2025, a decline of 47.5% year-over-year, but exceeded the Zacks Consensus Estimate by 18.9% [1][2] - The company recorded a GAAP loss per share of $3.30, an improvement from a loss of$6.85 in the same quarter last year [2] - Total sales reached $38.59 billion, reflecting a year-over-year increase of 4.1$30.4 billion, with comparable sales rising 8.2%. Pharmacy sales grew by 8.9%, benefiting from higher branded drug inflation and prescription volume [4] - International: Revenues rose 0.6% year-over-year to $6.1 billion, with a 4.1$2.2 billion, with VillageMD sales down 6.2%, while CareCentrix and Shields saw increases of 6.5% and 29.7%, respectively [7] Financial Metrics - Gross profit decreased by 1.5% year-over-year to $6.93 billion, with a gross margin contraction of 103 basis points to 17.9$8.89 billion, leading to an adjusted operating loss of $1.96 billion compared to a loss of$881 million in the previous year [8][13] - Cash and cash equivalents at the end of Q2 were $702 million, down from$859 million at the end of Q1, while total debt decreased to $8.02 billion from$8.39 billion [10] Strategic Developments - On March 6, 2025, WBA signed an agreement to be acquired by entities affiliated with Sycamore Partners, with the transaction expected to close in Q4 2025, resulting in WBA becoming a private company [11] - The company has withdrawn its fiscal 2025 guidance in light of the pending acquisition [11] Market Reaction - Following the earnings announcement, Walgreens shares declined by 1.1%, closing at $10.59 [2]